Ursa Brown Glaberman, MD
Hematology & Oncology · Albuquerque, NMNPI 1821292160
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Seagen Inc. at 41.0% of the total. Among hematology & oncology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $964.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$90K
- Gilead$64K
- Novartis$31K
- AstraZeneca$10K
- Eli Lilly$8K
- Stemline Therapeutics Inc.$4K
- plus $13K from 16 others
Across 202 payments — averaging $23,990 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.4M
- Pfizer$385K
- Seagen Inc.$298K
- Radius Health, Inc.$185K
- E.r. Squibb & Sons, L.L.C.$148K
- Genentech, Inc.$125K
- plus $333K from 7 others
What the payments were for
- Consulting fees$68,84031%
- Speaking & faculty fees$123,69956%
- Travel & lodging$21,08010%
- Food & beverage$5,2972%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 46 | $89,705 |
| Gilead | 69 | $63,597 |
| Novartis | 43 | $30,592 |
| AstraZeneca | 15 | $10,289 |
| Eli Lilly | 4 | $8,200 |
| Stemline Therapeutics Inc. | 3 | $3,597 |
| Daiichi Sankyo Inc. | 8 | $3,370 |
| Sanofi | 1 | $2,835 |
| Eisai Inc. | 5 | $2,152 |
| Taiho Oncology, Inc. | 1 | $1,875 |
| Pfizer | 17 | $1,259 |
| Halozyme Inc | 1 | $900 |
| Novocure Inc. | 1 | $131 |
| Exelixis Inc. | 1 | $116 |
| Macrogenics, Inc. | 1 | $91 |
| Sandoz | 1 | $89 |
| Caris MPI, Inc. | 1 | $78 |
| Merck | 5 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Incyte Corporation | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$219,006 in reported general payments places this provider in the 95th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 24 | $442 |
| Prochlorperazine Maleate | 23 | $356 |
| Ondansetron Hcl | 20 | $178 |
| Gabapentin | 15 | $114 |
| Tramadol Hcl | 13 | $91 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Albuquerque
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
- Bernard TawfikAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.